Evidence map›Paper›PMID 36181621›Full record

ArticleClinical journal of gastroenterology2022

A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.

Tatsuaki Sumiyoshi, Kenichiro Uemura, Ryuta Shintakuya, Kenjiro Okada, Hiroyuki Otsuka, Masahiro Serikawa, Yasutaka Ishii, Tomofumi Tsuboi, Koji Arihiro, Shinya Takahashi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tatsuaki SumiyoshiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Kenichiro UemuraDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. umk@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0003-0003-6268
Ryuta ShintakuyaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Kenjiro OkadaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroyuki OtsukaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Masahiro SerikawaDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Yasutaka IshiiDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Tomofumi TsuboiDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University, Hiroshima, Japan.
Shinya TakahashiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard chemotherapy for patients with unresectable cholangiocarcinoma is gemcitabine plus cisplatin, and gemcitabine plus S-1 (GS) chemotherapy is also reported to have similar effectiveness in Japan. However, the response rates of these two chemotherapies were modest, and no patients with intrahepatic cholangiocarcinoma (ICC) have shown a pathological complete response (pCR) following these chemotherapies. We report here the first case of an initially unresectable locally advanced ICC that achieved pCR following GS chemotherapy.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBile Ducts, IntrahepaticGemcitabineHumansGemcitabineGemcitabineIntrahepatic cholangiocarcinomaPathological complete responseS-1

Identifiers

PMID36181621
OpenAlexW4298326765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.